NCT05614817View on ClinicalTrials.gov

CBP-201 in Adolescent and Adult Patients With Moderate-to-severe Atopic Dermatitis

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2022

Primary Completion Date

August 31, 2024

Study Completion Date

July 31, 2025

Conditions
Atopic Dermatitis
Interventions
DRUG

CBP-201

CBP-201 subcutaneous(SC) injection

DRUG

Placebo

subcutaneous(SC) injection

Sponsors
All Listed Sponsors
lead

Connect Biopharm LLC

INDUSTRY

NCT05614817 - CBP-201 in Adolescent and Adult Patients With Moderate-to-severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter